A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This study was designed to explore the safety and efficacy of Bevacizumab combined with
Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with
platinum-resistant recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Second Affiliated Hospital of Shandong First Medical University